Literature DB >> 7525176

[Tumor vascular invasion in breast carcinoma. Hematoxylin-eosin versus immunohistochemical staining for factor VIII antigen].

A Obermair1, K Czerwenka, C Kurz, A Kaider, P Sevelda.   

Abstract

Blood vessel invasion was investigated with haematoxylin-eosin (HE) staining and immunohistochemical staining for factor VIII antigen (F VIII) in 106 patients with primary carcinoma of the breast, in order to compare their value in prognosticating the probability of recurrence. Blood vessel invasion was diagnosed in 65 cases (61.9%) by HE, but in only 45 (43.4%) by F VIII staining. Lymph-node status and blood vessel invasion correlated positively on HE (r = 0.73; P = 0.0001), but not so on F VIII staining. Multivariate logistic regression showed blood vessel invasion to be a strongly independent prognostic factor for recurrence-free survival with F VIII staining (odds ratio: = 7.19; P = 0.0001), while HE staining was not independent from other prognostic factors. These preliminary data thus suggest that demonstrating vascular invasion by F VIII staining may identify those patients with a very high risk of recurrence, independent of lymph-node status.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525176     DOI: 10.1055/s-2008-1058863

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  The influence of angiogenesis research on management of patients with breast cancer.

Authors:  J Folkman
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

2.  Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

Authors:  G Viale; A Giobbie-Hurder; B A Gusterson; E Maiorano; M G Mastropasqua; A Sonzogni; E Mallon; M Colleoni; M Castiglione-Gertsch; M M Regan; K N Price; R W Brown; R Golouh; D Crivellari; P Karlsson; C Öhlschlegel; R D Gelber; A Goldhirsch; A S Coates
Journal:  Ann Oncol       Date:  2009-07-24       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.